Key Highlights

  • Shield Therapeutics Plc (LSE:STX) rose 7.14% on 30 September 2026, continuing a recovery from summer lows.
  • First-half Revenue rose 41% to $30.4 million, boosted by a $7.9 million milestone from its China partner.
  • The company reported EBIT profitability in the first half and reiterated its goal of profitability for 2026.
  • Commercially insured prescriptions grew 27%, offsetting pressure from New York Medicaid changes.
  • Total Accrufer prescriptions rose 21% to around 102,000.

Shield Therapeutics Plc (LSE:STX) gained 7.14% on Wednesday, 30 September 2026, extending a rebound that began after the shares fell sharply following interim results in late July. The specialty pharmaceutical company, which sells the iron deficiency treatment Accrufer in the US, is regaining investor confidence as it moves towards sustained profitability.

Why Shield Therapeutics Is in Focus

Shield's lead product is Accrufer, known as Feraccru in some markets, a non-salt oral iron therapy for adults with iron deficiency with or without anaemia. The product offers an alternative to traditional iron salts, which often cause gastrointestinal side effects, and to intravenous iron infusions. The US is Shield's main market, with partners handling sales in China, Japan, Canada and other regions.

The shares had a strong run in 2025, surging more than 300% over 12 months, before falling back in 2026. After interim results in July, the shares dropped more than 20% to near their lows. They have since recovered steadily.

Interim Results Recap

For the six months to 30 June 2026, Shield reported revenue up 41% to $30.4 million, boosted by a $7.9 million development milestone from its Chinese partner ASK and higher royalties. The company said it achieved EBIT profitability in the period and remained on track for profitability in 2026.

However, underlying second-quarter trading was softer. Changes to prior authorisation requirements for New York Medicaid prescriptions reduced Accrufer's average net price to $208 from $231. Shield responded by shifting its focus towards commercially insured patients, where prescriptions grew 27%. Total prescriptions rose 21% to around 102,000.

Shield also secured its first group purchasing organisation contract, opening access to more than 400 clinics, and appointed a new chief financial officer from 1 September.

Key Reasons Behind the 7.14% Gain

The first reason is profitability. Shield's achievement of EBIT profitability and its reiterated goal for 2026 mark a turning point for a company that has historically been loss-making.

The second reason is the commercial shift. Strong growth in commercially insured prescriptions shows that Shield can offset Medicaid pressures and improve its revenue mix.

The third reason is broker support. Brokers maintain buy ratings, with one suggesting the shares could triple if profitability is achieved.

The fourth reason is recovery momentum. The shares have risen from lows around 4.5p to above 5p, and technical traders are now following the trend.

Risks to Consider

Risks include cash levels, which fell to $8.3 million at the end of June, pricing pressure in the US, dependence on a single product, and competition from other iron treatments. Any need for additional funding could dilute shareholders.

What Investors Are Watching Next

Investors will watch for third-quarter prescription data, updates on the group purchasing organisation contract, progress in China and Japan, and confirmation of full-year profitability.

Conclusion

Shield Therapeutics Plc (LSE:STX) climbed 7.14% today as investors regained confidence in its path to profitability and commercial strategy for Accrufer. With prescriptions growing and profitability within reach, the shares are recovering, though cash and pricing remain key watch points.